Europe Launches Probe into Pharma DealsAlistair Dawber
The European Commission yesterday launched a probe into the pharmaceutical industry's settlements with generics firms, questioning whether such deals breech the EU's competition laws and restrict consumers' access to medicines. Increasingly, drugs companies, such as GlaxoSmithKline (GSK) and AstraZeneca (AZN) have struck deals with generic competitors in an effort to preserve revenues on high earning treatments. The move follows a report on the industry last year that promised action on delays in getting drugs to market.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Ivanka Trump Faces Courtroom Showdown Over $785 Sandals
- Uber Losing Battle in London After Regulator Revokes License
- Mercedes Plots Tesla Attack With $1 Billion U.S. Electric Push
- Hewlett Packard Enterprise Is Said to Plan About 5,000 Job Cuts
- How Electric Cars Can Create the Biggest Disruption Since the iPhone